Lisata Therapeutics
LSTA | NASDAQ
$1.09
-$0.12 (-9.92%)
At close: Nov 16, 2026, 4:00 PM ET
$1.10
+$0.01 (+0.94%)
After-hours:
Nov 16, 2026, 5:56 PM ET
Lisata Therapeutics Company Profile
Company profile explainedCompany Profile
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Key Executives
| Name | Position |
|---|---|
| David J. Mazzo | Chief Executive Officer & Director |
| James Nisco | SVP of Finance and Treasury & Chief Accounting Officer |
| Joshua Lehrer-Graiwer FACC | President & COO |
| Tariq Imam | Head of Human Resources, Senior VP of Business Development & Operations and General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 19, 2026 | ARS | Filing |
| Oct 19, 2026 | DEF 14A | Filing |
| Oct 15, 2026 | 3 | Filing |
| Oct 14, 2026 | 8-K | Current Report |
| Oct 07, 2026 | PRE 14A | Filing |
| Oct 02, 2026 | D | Filing |
| Sep 28, 2026 | 3 | Filing |
| Sep 28, 2026 | 3 | Filing |
| Sep 17, 2026 | 8-K | Current Report |
| Aug 26, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
Lisata Therapeutics
| Country | United States |
| IPO Date | Mar 1, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | David J. Mazzo |
Contact Details
110 Allen Road Basking Ridge,
New Jersey 07920 United States
Stock Details
| Ticker Symbol | LSTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000320017 |
| CUSIP Number | 128058302 |
| ISIN Number | US1280583022 |
| SIC Code | 8090 |
Add to Watchlist
Select watchlists to add or remove LSTA